Table 3.
COVID-19 outcomes within 30 days after the index date by outpatient SARS-CoV-2 treatment status
| All patients (n=704) |
Outpatient treatment |
No outpatient treatment (n=278) | |||
|---|---|---|---|---|---|
| Any outpatient treatment (n=426)* | Nirmatrelvir–ritonavir (n=307) | Monoclonal antibodies (n=105) | |||
| Hospitalisation | 58 (8·2%) | 9 (2·1%) | 4 (1·3%) | 5 (4·8%) | 49 (17·6%) |
| Death | 3 (0·4%) | 1 (0·2%) | 1 (0·3%) | 0 | 2 (0·7%) |
| Severe COVID-19 (hospitalisation or death) | 58 (8·2%) | 9 (2·1%) | 4 (1·3%) | 5 (4·8%) | 49 (17·6%) |
| COVID-19 rebound† | NA | NA | 24/311‡ (7·7%) | NA | NA |
Data are n (%) or n/N (%). NA=not applicable.
There were no severe COVID-19 outcomes among patients who received other outpatient treatments (five patients received molnupiravir, three received remdesivir, and six received combination treatment [four received nirmatrelvir–ritonavir and monoclonal antibodies and two received molnupiravir and monoclonal antibodies]).
Within 7 days after completion of the oral outpatient regimen.
The denominator for COVID-19 rebound also includes four patients who received nimatrelvir–ritonavir in combination with monoclonal antibodies; there was also one COVID-19 rebound case among seven (14·3%) patients who received molnupiravir.